NCT02682641 2024-02-26
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Unknown
Clinical Trials
59 trialsNCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
NCT05290090 2023-10-17
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05979948 2023-09-14
CZ-WM01
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05887726 2023-07-27
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05940051 2023-07-11
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04433156 2023-05-18
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT05073250 2023-05-12
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT03688451 2023-03-29
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
University of Cincinnati
Phase 2 Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT05498259 2023-02-03
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01811368 2022-11-30
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Unknown
NCT05575973 2022-10-12
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Phase 2 Unknown
NCT05504603 2022-08-17
Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03736616 2022-07-22
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Phase 2 Unknown
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04989621 2022-03-24
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Phase 2 Unknown
NCT05200312 2022-03-11
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT05049473 2021-09-20
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Phase 2 Unknown
NCT04994626 2021-08-06
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
ChineseAMS
Phase 2 Unknown
NCT03949062 2021-02-17
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04622579 2020-11-10
R2DLBCL80
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT04425824 2020-06-16
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
ChineseAMS
Phase 2 Unknown
NCT03746223 2019-10-09
Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT01670370 2019-02-15
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT01429610 2018-07-24
RADICAL
Asan Medical Center
Phase 2 Unknown
NCT02753647 2017-11-14
Chidamide Plus R-CHOP in Elderly DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT01279902 2016-07-26
Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL
Asan Medical Center
Phase 2 Unknown
NCT02792491 2016-06-09
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Pusan National University Hospital
Phase 2 Unknown
NCT02758925 2016-05-04
CyBeR-Lymph
University Hospital, Caen
Phase 2 Unknown
NCT02753062 2016-04-27
PTLD
Asan Medical Center
Phase 2 Unknown
NCT00795613 2015-10-19
HD0607
Ospedale Santa Croce-Carle Cuneo
Phase 2 Unknown
NCT02456207 2015-05-28
A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
Sinocelltech Ltd.
Phase 2 Unknown
NCT01521689 2015-03-20
LLCRlowdoz
Institut Paoli-Calmettes
Phase 2 Unknown
NCT02142335 2014-05-20
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
California Cancer Assocaties for Research & Excellence
Phase 2 Unknown
NCT00258336 2014-01-10
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005959 2013-12-04
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00974792 2013-08-26
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00893477 2013-08-02
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00896519 2013-08-02
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01810926 2013-03-14
T&B Depletion Non Malignant
Bambino Gesù Hospital and Research Institute
Phase 2 Unknown
NCT01278602 2013-03-05
R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma
Fudan University
Phase 2 Unknown
NCT00772655 2012-08-02
Zevalin® First Line in Follicular Lymphoma
Charite University, Berlin, Germany
Phase 2 Unknown
NCT01181999 2011-09-22
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Chonnam National University Hospital
Phase 2 Unknown